{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T21:08:05Z","timestamp":1794344885236,"version":"4.9.0"},"reference-count":98,"publisher":"Elsevier BV","issue":"44","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.vaccine.2015.06.110","type":"journal-article","created":{"date-parts":[[2015,7,16]],"date-time":"2015-07-16T01:51:52Z","timestamp":1437011512000},"page":"5905-5912","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["Cell substrates for the production of viral vaccines"],"prefix":"10.1016","volume":"33","author":[{"given":"Fran\u00e7oise","family":"Aubrit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Perugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"L\u00e9on","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Gu\u00e9henneux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Champion-Arnaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Lahmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Schwamborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2015.06.110_bib0495","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1001\/jama.298.18.2155","article-title":"Murphy TV, and the vaccine-preventable disease table working group. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States","volume":"298","author":"Roush","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0500","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2471\/BLT.07.040089","article-title":"Vaccination greatly reduces disease, disability, death and inequity worldwide","volume":"86","author":"Andre","year":"2008","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0505","series-title":"An inquiry into the causes and effects of the variolae vaccinae","author":"Jenner","year":"1798"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0510","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1126\/science.74.1919.371","article-title":"The cultivation of vaccine and other viruses in the chorioallantoic membrane of chick embryos","volume":"74","author":"Goodpasture","year":"1931","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0515","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1016\/S0264-410X(03)00071-9","article-title":"The annual production cycle of influenza vaccine","volume":"21","author":"Gerdil","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0520","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1586\/erv.12.24","article-title":"Cell culture-derived influenza vaccines from Vero cells: a new horizon for vaccine production","volume":"11","author":"Montomoli","year":"2012","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0525","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.2165\/00003495-200868110-00002","article-title":"Cell-based Influenza vaccines: progress to date","volume":"68","author":"Audsley","year":"2008","journal-title":"Drugs"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0530","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.biologicals.2008.07.001","article-title":"New technologies for meeting the global demand for pandemic influenza vaccines","volume":"26","author":"Fedson","year":"2008","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0535","doi-asserted-by":"crossref","first-page":"994","DOI":"10.2105\/AJPH.44.8.994","article-title":"Studies in human subjects on active immunization against poliomyelitis. II. A practical means for inducing and maintaining antibody formation","volume":"44","author":"Salk","year":"1954","journal-title":"Am J Public Health Nations Health"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0540","first-page":"214","article-title":"Use of color change of phenol red as the indicator in titrating poliomyelitis virus or its antibody in a tissue-culture system","volume":"60","author":"Salk","year":"1954","journal-title":"Am J Hyg"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0545","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1023\/A:1008094017583","article-title":"Historical reflections on cell culture engineering","volume":"28","author":"Lubiniecki","year":"1998","journal-title":"Cytotechnology"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0550","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.3390\/v6041672","article-title":"Matrix and backstage: cellular substrates for viral vaccines","volume":"6","author":"Jordan","year":"2014","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0555","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/227168a0","article-title":"Characteristics of a Human diploid cell designated MRC-5","volume":"227","author":"Jacobs","year":"1970","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0560","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/0014-4827(61)90192-6","article-title":"The serial cultivation of human diploid cell substrates","volume":"25","author":"Hayflick","year":"1961","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0565","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3181\/00379727-98-24111","article-title":"Established kidney cell lines of normal adult bovine and ovine origin","volume":"98","author":"Madin","year":"1958","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0570","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3181\/00379727-122-31293","article-title":"Characterization of an established line of canine kidney cells (MDCK)","volume":"122","author":"Gausch","year":"1966","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0575","first-page":"1201","article-title":"Studies on SV40 in tissue culture\u2013Preliminary step for cancer research in vitro","volume":"21","author":"Yasumura","year":"1963","journal-title":"Nihon Rinsho"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0580","unstructured":"Food and Drug Administration History and characterization of the Vero cell line. A report prepared by CDR Rebecca Sheets, Ph. D., USPHS. CBER\/OVRR\/DVRPA\/VVB for the Vaccines and Related Biological Products Advisory Committee Meeting to be held on May 12, 2000. Available at http:\/\/www.fda.gov\/ohrms\/dockets\/AC\/00\/backgrd\/3616b1a.pdf."},{"key":"10.1016\/j.vaccine.2015.06.110_bib0585","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/biot.201400388","article-title":"Designing cell lines for viral vaccine production: where do we stand","volume":"10","author":"Genzel","year":"2015","journal-title":"Biotechnol J"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0595","unstructured":"Food and Drug Administration. Designer cells as substrates for the manufacture of viral vaccines. Available at: http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/01\/briefing\/3750b1_01.htm."},{"key":"10.1016\/j.vaccine.2015.06.110_bib0590","first-page":"419","article-title":"The avian EB66\u00ae cell line, application to vaccines, and therapeutic protein production","volume":"64","author":"Brown","year":"2010","journal-title":"PDA J Pharm Sci Technol"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0600","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1089\/hum.1998.9.13-1909","article-title":"New helper cells and matched early region 1 deleted adenovirus vectors prevent generation of replication competent adenoviruses","volume":"9","author":"Fallaux","year":"1998","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0605","series-title":"Modern Biopharmaceuticals: design, development and optimization","article-title":"Per. C6 cells for the manufacture of biopharmaceutical proteins","author":"Yallop","year":"2005"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0610","doi-asserted-by":"crossref","first-page":"748e56","DOI":"10.1016\/j.vaccine.2008.11.066","article-title":"An avian cell line designed for production of highly attenuated viruses","volume":"27","author":"Jordan","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0615","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00253-012-4238-2","article-title":"CAP, a new human suspension cell line for influenza virus production","volume":"97","author":"Genzel","year":"2013","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0620","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1586\/erv.09.128","article-title":"Continuous cell lines as a production system for influenza vaccines","volume":"8","author":"Genzel","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0625","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.biologicals.2014.07.003","article-title":"Adventitious agents in viral vaccines: lessons learned from 4 case studies","volume":"42","author":"Petricciani","year":"2014","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0630","doi-asserted-by":"crossref","first-page":"420","DOI":"10.3181\/00379727-105-26128","article-title":"The vacuolating virus, S.V. 40","volume":"105","author":"Sweet","year":"1960","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0635","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/oxfordjournals.aje.a112197","article-title":"Human exposure to SV40: review and comment","volume":"103","author":"Shah","year":"1976","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0640","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0092-1157(75)90034-7","article-title":"Bacteriophage contamination in live poliovirus vaccine","volume":"3","author":"Milch","year":"1975","journal-title":"J Biol Stand"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0645","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1093\/infdis\/131.5.588","article-title":"Bacteriophages and endotoxin in licensed live-virus vaccines","volume":"131","author":"Moody","year":"1975","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0650","doi-asserted-by":"crossref","first-page":"6033","DOI":"10.1128\/JVI.02690-09","article-title":"Viral nucleic acids in live-attenuated vaccines: detection of minority variants and an adventitious virus","volume":"84","author":"Victoria","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0655","doi-asserted-by":"crossref","unstructured":"Knezevic I, Stacey G, Petricciani J, WHO Study Group on cell substrates. WHO Study Group on cell substrates for production of biologicals, Geneva, Switzerland, 11-12 June 2007. Biologicals, 2008;36:203-11.","DOI":"10.1016\/j.biologicals.2007.11.005"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0660","unstructured":"WHO Expert Committee on Biological Standardization. Sixty-first report. WHO Technical Report Series, No. 978, 2013 Annex 3. Recommendations for the evaluation of animal cell cultures as substrates for the manufacture of biological medicinal products and for the characterization of cell banks. Available at: http:\/\/www.who.int\/biologicals\/expert_committee\/TRS_978_61st_report.pdf."},{"key":"10.1016\/j.vaccine.2015.06.110_bib0665","unstructured":"ICH Topic Q5A (R1). Quality of biotechnological products: viral safety evaluation of biotechnology products derived from cell lines of human or animal origin. CPMP\/ICH\/295\/95. 1997. Available at: http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Quality\/Q5A_R1\/Step4\/Q5A_R1__Guideline.pdf."},{"key":"10.1016\/j.vaccine.2015.06.110_bib0670","unstructured":"ICH Topic Q5D. Quality of biotechnological products: derivation and characterization of cell substrates used for production of biotechnological\/biological products. CPMP\/ICH\/294\/95. 1998. Available at: http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Quality\/Q5D\/Step4\/Q5D_Guideline.pdf."},{"key":"10.1016\/j.vaccine.2015.06.110_bib0675","unstructured":"Food and Drug Administration Center for Biologics Evaluation and Research. Guidance for industry. Characterization and qualification of cell substrates and other biologicals materials used in the production of viral vaccines for infectious disease indications. February 2010. Available at: http:\/\/www.fda.gov\/downloads\/biologicsblood vaccines\/guidancecomplianceregulatoryinformation\/guidances\/vaccines\/ucm202439.pdf."},{"key":"10.1016\/j.vaccine.2015.06.110_bib0680","unstructured":"European Pharmacopoeia 5.0. 5.2.3. Cell substrates for the production of vaccines for human use. January 2005. Available at: http:\/\/lib.njutcm.edu.cn\/yaodian\/ep\/EP5.0\/05_general_texts\/5.2.__general_texts_on_vaccines\/5.2.3.%20Cell%20substrates%20for%20the%20production%20of%20vaccines%20for%20human%20use.pdf."},{"key":"10.1016\/j.vaccine.2015.06.110_bib0685","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1177\/026119290503300313","article-title":"Guidance on good cell culture practice. A report of the second ECVAM task force on good cell culture practice","volume":"33","author":"Coecke","year":"2005","journal-title":"Altern Lab Anim"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0690","first-page":"264","article-title":"Tissue culture studies of the proliferative capacity of cervical carcinoma and normal epithelium","volume":"12","author":"Gey","year":"1952","journal-title":"Cancer Res"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0695","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.5858\/133.9.1463","article-title":"Henrietta Lacks, HeLa cells, and cell culture contamination","volume":"133","author":"Lucey","year":"2009","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0700","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1006\/viro.1997.8597","article-title":"Cloning and sequencing of the cellular-viral junctions from the human adenovirus type 5 transformed 293 cell line","volume":"233","author":"Louis","year":"1997","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0705","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1023\/A:1008005026243","article-title":"Collective experiences of adventitious viruses of animal-derived raw materials and what can be done about them","volume":"28","author":"Wessman","year":"1998","journal-title":"Cytotechnology"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0710","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.biologicals.2011.08.003","article-title":"Evaluation of the human host range of bovine and porcine viruses that may contaminate bovine serum and porcine trypsin used in the manufacture of biological products","volume":"39","author":"Marcus-Sekura","year":"2011","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0715","unstructured":"European Commission Note for guidance on minimising the risk of transmitting animal spongiform encephalopathy agents via human and veterinary medicinal products (EMA\/410\/01 rev.3). Official Journal of the European Union, 2011\/C 73\/01. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003700.pdf."},{"key":"10.1016\/j.vaccine.2015.06.110_bib0720","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1093\/nar\/21.15.3593","article-title":"An RT-PCR assay for the enzyme activity of reverse transcriptase capable of detecting single virions","volume":"21","author":"Silver","year":"1993","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0725","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1073\/pnas.91.4.1544","article-title":"Ultrasensitive retrovirus detection by a reverse transcriptase assay based on product enhancement","volume":"91","author":"Pyra","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0730","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0928-0197(95)00159-X","article-title":"Detection of reverse transcriptase activity in live attenuated virus vaccines","volume":"5","author":"B\u00f6ni","year":"1996","journal-title":"Clin Diagn Virol"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0735","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.biologicals.2009.02.016","article-title":"Proposed algorithm to investigate latent and occult viruses in vaccine cell substrates by chemical induction","volume":"37","author":"Khan","year":"2009","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0740","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/978-1-61779-582-4_5","article-title":"Next-generation sequencing technologies and fragment assembly algorithms","volume":"855","author":"Lee","year":"2012","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0745","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1186\/1471-2164-11-668","article-title":"A microbial detection array (MDA) for viral and bacterial detection","volume":"11","author":"Gardner","year":"2010","journal-title":"BMC Genomics"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0750","unstructured":"Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee. Meeting Materials. Available at http:\/\/www.fda.gov\/AdvisoryCommittees\/CommitteesMeetingMaterials\/BloodVaccinesandOtherBiologics\/VaccinesandRelatedBiologicalProductsAdvisoryCommittee\/."},{"key":"10.1016\/j.vaccine.2015.06.110_bib0755","first-page":"513","article-title":"A defined-risks approach to the regulatory assessment of the use of neoplastic cells as substrates for viral vaccine manufacture","volume":"106","author":"Lewis","year":"2001","journal-title":"Dev Biol (Basel)"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0760","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.biologicals.2007.06.002","article-title":"Assessing the tumorigenic phenotype of Vero cells in adult and newborn nude mice","volume":"36","author":"Manohar","year":"2008","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0765","first-page":"16","article-title":"Considerations in scale-up of viral vaccine production","volume":"9S","author":"Whitford","year":"2011","journal-title":"Bioprocess Int"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0770","first-page":"8","article-title":"Simpler and more efficient viral vaccine manufacturing","volume":"11S","author":"Moncaubeig","year":"2013","journal-title":"BioProcess Int"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0775","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13568-014-0025-z","article-title":"Assessment of packed bed bioreactor systems in the production of viral vaccines","volume":"4","author":"Rajendran","year":"2014","journal-title":"AMB Express"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0780","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/216064a0","article-title":"Growth of cell-strains and primary cells on micro-carriers in homogeneous culture","volume":"216","author":"van Wezel","year":"1967","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0785","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/btpr.262","article-title":"Growth behavior of number distributed adherent MDCK cells for optimization in microcarrier cultures","volume":"25","author":"Bock","year":"2009","journal-title":"Biotechnol Prog"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0790","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/978-1-59745-399-8_5","article-title":"Microcarrier cell culture technology","volume":"24","author":"Bl\u00fcml","year":"2007","journal-title":"Anim Cell Biotechnol Method Protocol"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0795","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s00253-011-3860-8","article-title":"MDCK cell-cultured influenza virus vaccine protects mice from lethal challenge with different influenza viruses","volume":"94","author":"Liu","year":"2012","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0800","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s00253-011-3574-y","article-title":"Development of a measles vaccine production process in MRC-5 cells grown on Cytodex1 microcarriers and in a stirred bioreactor","volume":"93","author":"Trabelsi","year":"2012","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0805","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1586\/erv.12.55","article-title":"Preflucel\u00ae: a Vero-cell culture-derived trivalent influenza vaccine","volume":"11","author":"Chan","year":"2012","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0810","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/bit.260290117","article-title":"Hydrodynamic effects on animal cells grown in microcarrier cultures","volume":"29","author":"Croughan","year":"1987","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0815","unstructured":"Calvosa E, Seve N. Process for culturing adherent cells. Patent US 20110151506 A1. 23 June 2011."},{"key":"10.1016\/j.vaccine.2015.06.110_bib0820","article-title":"Culturing a duck ES-derived cell line in single-use bioreactors: a rapid, efficient, and cost-effective vaccine manufacturing system based on suspension culture","author":"Madeline","year":"2015","journal-title":"BioProcess Int"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0825","article-title":"The role of media development in process optimization: An historical perspective","author":"Grosvenor","year":"2008","journal-title":"BioPharm Int Suppl"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0830","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2015.04.050","article-title":"Increasing Vero viable cell densities for yellow fever virus production in stirred-tank bioreactors using serum-free medium","author":"Mattos","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0835","doi-asserted-by":"crossref","DOI":"10.1007\/s00253-015-6636-8","article-title":"Production of canine adenovirus type 2 in serum-free suspension cultures of MDCK cells","author":"Castro","year":"2015","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0840","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/bit.10644","article-title":"Large-scale propagation of a replication-defective adenovirus vector in stirred-tank bioreactor PER.C6 cell culture under sparging conditions","volume":"83","author":"Xie","year":"2003","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0845","first-page":"38","article-title":"Optimization of cell culture media","volume":"3S","author":"Jerums","year":"2005","journal-title":"BioProcess Int"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0850","series-title":"Cell culture technology for pharmaceutical and cell-based therapies","author":"Ozturk","year":"2005"},{"issue":"9","key":"10.1016\/j.vaccine.2015.06.110_bib0855","doi-asserted-by":"crossref","first-page":"e72288","DOI":"10.1371\/journal.pone.0072288","article-title":"Continuous influenza virus production in cell culture shows a periodic accumulation of defective interfering particles","volume":"8","author":"Frensing","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0860","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/sj.gt.3302624","article-title":"Downstream processing of viral vectors and vaccines","volume":"12","author":"Morenweiser","year":"2005","journal-title":"Gene Ther"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0865","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1586\/erv.11.111","article-title":"Downstream processing of cell culture-derived virus particles","volume":"10","author":"Wolff","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0870","series-title":"Vaccine analysis: strategies, principles and controls","author":"Nunnally","year":"2015"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0875","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.biologicals.2009.02.015","article-title":"Issue associated with residual cell-substrate DNA in viral vaccines","volume":"37","author":"Sheng-Fowler","year":"2009","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0880","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.biologicals.2009.04.002","article-title":"Quantitative determination of the infectivity of the proviral DNA of a retrovirus in vitro: evaluation of methods for DNA inactivation","volume":"37","author":"Sheng-Fowler","year":"2009","journal-title":"Biologicals"},{"issue":"1","key":"10.1016\/j.vaccine.2015.06.110_bib0885","first-page":"22","article-title":"Facility of the future: next generation biomanufacturing forum. Part I: why we cannot stay here\u2013The challenges, risks, and business drivers for changing the paradigm","volume":"33","author":"Witcher","year":"2013","journal-title":"Pharmaceut Eng"},{"issue":"S4","key":"10.1016\/j.vaccine.2015.06.110_bib0890","first-page":"27","article-title":"When the process becomes the products: single-use technology and the next biomanufacturing paradigm","volume":"26","author":"Pralong","year":"2013","journal-title":"BioPharm Int"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0895","first-page":"1","article-title":"Biopharmaceutical manufacturing in the twenty-first century\u2013the next generation manufacturing facililty","volume":"32","author":"Witcher","year":"2012","journal-title":"Pharmaceut Eng"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0900","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/elsc.201400027","article-title":"Paradigm shift for vaccine manufacturing facilities: the next generation of flexible, modular facilities","volume":"14","author":"Pralong","year":"2014","journal-title":"Eng Life Sci"},{"issue":"2","key":"10.1016\/j.vaccine.2015.06.110_bib0905","first-page":"32","article-title":"Facility of the future: next generation biomanufacturing forum. Part II: tools for change\u2013Enabling technologies and business and regulatory approaches","volume":"33","author":"Witcher","year":"2013","journal-title":"Pharmaceut Eng"},{"issue":"3","key":"10.1016\/j.vaccine.2015.06.110_bib0910","first-page":"36","article-title":"Facility of the future: next generation biomanufacturing forum. Part III: identifying facility requirements based on specific business drivers and uncertainties using the enabling technologies","volume":"33","author":"Witcher","year":"2013","journal-title":"Pharmaceut Eng"},{"issue":"S6","key":"10.1016\/j.vaccine.2015.06.110_bib0915","first-page":"65","article-title":"A decade of manufacturing","volume":"10","author":"Langer","year":"2012","journal-title":"BioProcess Int"},{"issue":"4","key":"10.1016\/j.vaccine.2015.06.110_bib0920","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/bit.25529","article-title":"The future of industrial bioprocessing: batch or continuous?","volume":"112","author":"Croughan","year":"2015","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0925","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1128\/JVI.71.4.3005-3012.1997","article-title":"Reverse transcriptase activity in chicken embryo fibroblast culture supernatants is associated with particles containing endogenous avian retrovirus EAV-0 RNA","volume":"71","author":"Weissmahr","year":"1997","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0930","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.biologicals.2010.04.003","article-title":"Validation of the safety of MDCK cells as a substrate for the production of a cell-derived influenza vaccine","volume":"38","author":"Onions","year":"2010","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0935","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1016\/j.vaccine.2014.04.072","article-title":"Development and preclinical testing of HNVAC, a cell culture-based H1N1 pandemic influenza vaccine from India","volume":"32","author":"Hegde","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0940","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2217\/fmb.10.161","article-title":"Safety of MDCK cell culture-based influenza vaccines","volume":"6","author":"Gregersen","year":"2011","journal-title":"Future Microbiol"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0945","unstructured":"WHO Expert Committee on Biological Standardization. Forty-seventh report. WHO Technical Report Series, No. 878, 1998. Available at: http:\/\/apps.who.int\/medicinedocs\/documents\/s16109e\/s16109e.pdf."},{"key":"10.1016\/j.vaccine.2015.06.110_bib0950","first-page":"251","article-title":"Tumorigenicity assessments of Per.C6 cells and of an Ad5-vectored HIV-1 vaccine produced on this continuous cell line","volume":"123","author":"Ledwith","year":"2006","journal-title":"Dev Biol"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0955","series-title":"Characterization of the avian designer cells AGE1.CR and AGE1.CR.plX considering growth, metabolism and production of influenza virus and Modified Vaccinia Virus Ankara (MVA)","author":"Lohr","year":"2014"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0960","doi-asserted-by":"crossref","first-page":"6256","DOI":"10.1016\/j.vaccine.2010.07.004","article-title":"A new MDCK suspension line cultivated in a fully defined medium in stirred-tank and wave bioreactor","volume":"28","author":"Lohr","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0965","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/bit.10917","article-title":"Rabies virus production in high vero cell density cultures on macroporous microcarriers","volume":"85","author":"Yokomizo","year":"2004","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0970","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1472-6750-14-72","article-title":"The avian cell line AGE1.CR.pIX characterized by metabolic flux analysis","volume":"14","author":"Lohr","year":"2014","journal-title":"BMC Biotechnol"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0975","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/978-1-62703-733-4_23","article-title":"Vaccine production: upstream processing with adherent or suspension cell lines","volume":"1104","author":"Genzel","year":"2014","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.vaccine.2015.06.110_bib0980","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1016\/j.vaccine.2014.02.016","article-title":"High cell density cultivations by alternating tangential flow (ATF) perfusion for influenza A virus production using suspension cells","volume":"32","author":"Genzel","year":"2014","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15009329?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15009329?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T00:39:11Z","timestamp":1717979951000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X15009329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":98,"journal-issue":{"issue":"44","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S0264410X15009329"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.06.110","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cell substrates for the production of viral vaccines","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.06.110","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}